复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02196 复星医药

休市中 12-05 16:09:08

21.480

+0.220

+1.03%

最高21.480	最低21.000	成交量173.15万
今开21.300	昨收21.260	日振幅2.26%
总市值571.15亿	流通市值116.20亿	总股本26.59亿
成交额3,688万	换手率0.32%	流通股本5.41亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02196","market":"HK","secType":"STK","nameCN":"复星医药","latestPrice":21.48,"timestamp":1764922148002,"preClose":21.26,"halted":0,"volume":1731511,"delay":0,"floatShares":540971500,"shares":2659000000,"eps":1.1420398556058977,"marketStatus":"休市中","change":0.22,"latestTime":"12-05 16:09:08","open":21.3,"high":21.48,"low":21,"amount":36880702,"amplitude":0.022578,"askPrice":21.48,"askSize":1000,"bidPrice":21.44,"bidSize":13500,"shortable":3,"etf":0,"ttmEps":1.3628855501113237,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765157400000},"marketStatusCode":7,"adr":0,"listingDate":1351526400000,"exchange":"SEHK","adjPreClose":21.26,"dividendRate":0.016399,"openAndCloseTimeList":[[1764898200000,1764907200000],[1764910800000,1764921600000]],"volumeRatio":0.810935,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600196","market":"SH","secType":"STK","nameCN":"复星医药","latestPrice":27.14,"timestamp":1764918000000,"preClose":26.97,"halted":0,"volume":10041300,"delay":0,"premium":"-28.12"}},"requestUrl":"/m/hq/s/02196","defaultTab":"news","newsList":[{"id":"2589402852","title":"【券商聚焦】交银国际：医药行业短期催化剂充足 长期继续看好创新主线","url":"https://stock-news.laohu8.com/highlight/detail?id=2589402852","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589402852?lang=zh_cn&edition=full","pubTime":"2025-12-05 10:38","pubTimestamp":1764902337,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际表示，2025年10月以来，内资通过港股通持有医药股的比例小幅下降，外资持仓从年中起亦呈回落态势，但内外资加大创新药布局的大方向不变。而外资则更积极，聚焦创新主线中的龙头及产业链上游，包括恒瑞医药、君实生物和荣昌生物等创新药，及康龙化成、药明康德和泰格医药等CXO标的。12月，行业仍有充足催化剂，包括各项学术大会、医保谈判结果公布、美联储潜在降息等，板块投资情绪有望稳中有升。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1970976","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B543WZ88.USD","LU1251922891.USD","01099","BK1197","BK1500","LU0634319403.HKD","LU1969619763.USD","LU2476274720.SGD","01789","LU0640798160.USD","LU0348766576.USD","IE00BPRC5H50.USD","01530","LU0540923850.HKD","BK1588","LU2476274308.USD","LU0417516571.SGD","BK1585","LU0417516902.SGD","BK1593","BK1141","03329","IE00B5MMRT66.SGD","LU2488822045.USD","LU1303224171.USD","LU2328871848.SGD","09688","LU0348825331.USD","LU2778985437.USD","BK1617","BK1147","02228","BK1583","SG9999014674.SGD","LU2399975544.HKD","LU0417516738.SGD","03933","02367","LU0348827113.USD","02268","LU1794554557.SGD","BK1161","02196","SG9999004311.SGD","LU0588546209.SGD","LU1770034418.SGD","LU0561508036.HKD","06160","09926","HK0000165453.HKD"],"gpt_icon":1},{"id":"2589372348","title":"复拓知达“一次性使用肺结节三维标识定位标记物”入选《上海市生物医药“新优药械”产品目录》","url":"https://stock-news.laohu8.com/highlight/detail?id=2589372348","media":"动脉网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589372348?lang=zh_cn&edition=full","pubTime":"2025-12-04 19:33","pubTimestamp":1764847980,"startTime":"0","endTime":"0","summary":"人民财讯12月4日消息，上海市科学技术委员会近日对《上海市生物医药“新优药械”产品目录》（第七批）进行公示，24款“新优药械”产品被列入该目录。其中，由复星诊疗科技旗下企业复拓知达自主研发的“一次性使用肺结节三维标识定位标记物”成功入选。这一成果标志着复拓知达在肺结节定位技术领域取得了重要突破，其产品得到了官方认可，有望为肺结节的精准定位和后续治疗提供更有效的辅助手段，对提升肺结节诊疗水平具有积极意义。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251204194633952ac653&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251204194633952ac653&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1593","BK1191","02196","BK1515"],"gpt_icon":0},{"id":"2589836627","title":"每日卖空追踪 | 复星医药 12月04日卖空量成交1.8万股，卖空比例为1.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2589836627","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589836627?lang=zh_cn&edition=full","pubTime":"2025-12-04 16:30","pubTimestamp":1764837029,"startTime":"0","endTime":"0","summary":"复星医药北京时间12月04日，涨0.85%，卖空量成交1.8万股，较上一交易日减少79.55%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251204163427978f8803&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251204163427978f8803&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1593","BK1191","02196","BK1515"],"gpt_icon":0},{"id":"2588009934","title":"复星医药2025年A股股票期权激励计划首次授予完成，182名激励对象获授444.64万份期权","url":"https://stock-news.laohu8.com/highlight/detail?id=2588009934","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588009934?lang=zh_cn&edition=full","pubTime":"2025-12-04 15:36","pubTimestamp":1764833770,"startTime":"0","endTime":"0","summary":"中访网数据 上海复星医药(集团)股份有限公司于2025年12月3日发布公告，宣布其2025年A股股票期权激励计划首次授予的登记工作已完成。本次激励计划首次授予的授予日为2025年11月4日，实际向182名激励对象授予了总计4,446,400份A股股票期权，约占公司当前总股本的0.1665%。　　根据激励计划安排，首次授予的A股期权将分三期行权，等待期分别为12个月、24个月和36个月。　　本次股权激励产生的股份支付费用将在激励计划实施过程中分期摊销。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251204/31844205.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0012","600196","BK0060","BK0096","BK0183","BK0188","BK0239","BK0175","02196","BK0028","BK0187","BK1593","BK1191","BK0196","159982","399300","BK1515"],"gpt_icon":0},{"id":"2588197860","title":"复星医药最新公告：控股子公司拟用于治疗晚期恶性实体瘤创新药物FXS887片获临床试验批准于全球范围内尚无同靶点的小分子抑制剂单药或联合治疗方案获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2588197860","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588197860?lang=zh_cn&edition=full","pubTime":"2025-12-03 16:56","pubTimestamp":1764752215,"startTime":"0","endTime":"0","summary":"复星医药(600196.SH)公告称，控股子公司上海复星医药产业发展有限公司（简称“复星医药产业”）收到国家药品监督管理局关于同意FXS887片（简称“FXS0887”）用于晚期恶性实体瘤开展临床试验的批准。FXS0887为本集团（即本公司及控股子公司/单位）自主研发的口服小分子创新药物，拟用于治疗晚期恶性实体瘤。截至本公告日期（即2025年12月3日），于全球范围内尚无同靶点的小分子抑制剂单药或联合治疗方案获批上市。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120300025352.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0183","BK0028","BK1191","159992","600196","BK0188","BK0012","BK1515","02196","BK0096","BK0175","06978","BK1593","BK0239","BK0196","BK0187","BK1161","BK1574"],"gpt_icon":0},{"id":"2588904689","title":"每日卖空追踪 | 复星医药 12月03日卖空量成交2.55万股，卖空比例为1.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588904689","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588904689?lang=zh_cn&edition=full","pubTime":"2025-12-03 16:30","pubTimestamp":1764750625,"startTime":"0","endTime":"0","summary":"复星医药北京时间12月03日，跌1.13%，卖空量成交2.55万股，较上一交易日减少81.32%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025120316340195286eea&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025120316340195286eea&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1593","02196","BK1515"],"gpt_icon":0},{"id":"2588046891","title":"年销超500亿骨质疏松症药物市场再迎竞逐者，复星医药上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2588046891","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588046891?lang=zh_cn&edition=full","pubTime":"2025-12-03 16:16","pubTimestamp":1764749770,"startTime":"0","endTime":"0","summary":"在此背景下，骨质疏松症用药市场潜力持续释放，其中地舒单抗随着原研药专利到期，国内地舒单抗生物类似药市场迅速升温。据悉，在该药物领域，国内又将迎来一家竞逐者。根据2025年12月3日CDE网站公示：复星医药地舒单抗注射液上市申请获受理，用于治疗绝经后妇女骨质疏松症、男性骨质疏松症及糖皮质激素诱导的骨质疏松症。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251203161919a4c9e597&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251203161919a4c9e597&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1191","BK1593","02196"],"gpt_icon":0},{"id":"2588879094","title":"流感高峰期来袭！抗流感概念反复活跃，上市公司密集回应市场关切","url":"https://stock-news.laohu8.com/highlight/detail?id=2588879094","media":"腾讯自选股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588879094?lang=zh_cn&edition=full","pubTime":"2025-12-03 10:22","pubTimestamp":1764728562,"startTime":"0","endTime":"0","summary":"亿帆医药公司人士表示，近期公司独家中药产品、用于治疗普通感冒和流感的复方银花解毒颗粒的销量同比已有一定提升，相关生产线目前处于满负荷生产状态。以岭药业工作人员表示，随着流感高峰期的到来，连花清瘟等产品未来销量预期会有所增长。展望后市，光大证券表示，近期流感疫情上升态势明显，可能引发社会公众和市场关注度的提升，从而带动防治和检测流感产品的需求增长。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512031013219527d73c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512031013219527d73c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02096","02607","BK1197","02196"],"gpt_icon":0},{"id":"2588067851","title":"复星医药旗下私募基金LP变更，大连金运接替大连融达成新合伙人","url":"https://stock-news.laohu8.com/highlight/detail?id=2588067851","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588067851?lang=zh_cn&edition=full","pubTime":"2025-12-03 07:58","pubTimestamp":1764719922,"startTime":"0","endTime":"0","summary":"中访网数据 上海复星医药(集团)股份有限公司于2025年12月2日发布公告，披露其参与设立的私募股权投资基金——大连星未来创业创新基金合伙企业发生有限合伙人变更。变更完成后，大连金运将持有基金29%的份额，成为新的有限合伙人。复星医药通过控股子公司大连复健和宁波复瀛合计认缴的2.55亿元出资额及51%的份额比例保持不变，基金总认缴规模仍为5亿元。大连金运由大连市财政局全资控股，与复星医药无关联关系。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251203/31839848.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0196","600196","BK0239","BK0187","BK0012","BK0060","BK0188","BK1191","BK0096","BK0183","02196","BK1515","BK0175","BK0028","BK1593"],"gpt_icon":0},{"id":"2588805956","title":"复星医药（600196）披露选举执行董事议案获股东会通过，12月2日股价下跌0.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588805956","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588805956?lang=zh_cn&edition=full","pubTime":"2025-12-02 22:08","pubTimestamp":1764684535,"startTime":"0","endTime":"0","summary":"截至2025年12月2日收盘，复星医药报收于27.09元，较前一交易日下跌0.88%，最新总市值为723.42亿元。该股当日开盘27.35元，最高27.35元，最低27.0元，成交额达2.65亿元，换手率为0.46%。公司近日发布公告称，上海复星医药（集团）股份有限公司于2025年12月2日召开2025年第二次临时股东会，会议由董事会召集，董事长陈玉卿主持，采用现场与网络结合方式召开。出席会议股东共1,726人，代表有表决权股份总数1,081,006,672股，占公司总股本的40.9541%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200039334.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0096","BK0028","BK0012","BK0196","BK1191","BK0060","BK1593","BK1515","BK0188","02196","BK0183","BK0187","600196","BK0239","BK0175"],"gpt_icon":0},{"id":"2588370540","title":"复星医药(02196)：刘毅获选举为执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2588370540","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588370540?lang=zh_cn&edition=full","pubTime":"2025-12-02 19:47","pubTimestamp":1764676050,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(02196)发布公告，于临时股东会上，刘毅先生获股东正式选举为第十届董事会执行董事，委任自2025年12月2日起生效至本届董事会任期届满为止。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1376693.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0187","BK0175","BK1593","BK0196","BK0096","BK0012","BK0188","BK0028","BK1515","02196","600196","BK0060","BK0183","BK1191","BK0239"],"gpt_icon":0},{"id":"2588311400","title":"复星医药子公司HLX14药品注册申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2588311400","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588311400?lang=zh_cn&edition=full","pubTime":"2025-12-02 18:10","pubTimestamp":1764670224,"startTime":"0","endTime":"0","summary":"12月2日，复星医药（600196/02196）发布公告，控股子公司上海复宏汉霖生物技术股份有限公司及其控股子公司自主研发的地舒单抗生物类似药HLX14的药品注册申请已获国家药品监督管理局受理。HLX14的适应症参照已在中国境内获批上市的药品普罗力?的所有适应症。HLX14目前已在美国、欧盟和英国获批上市，2024年9月，其在加拿大的上市注册申请也已获受理。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512023580475079.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0096","BK0028","BK0012","BK0196","BK1191","BK0060","BK1593","BK1515","BK0188","02196","BK0183","BK0187","600196","BK0239","BK0175"],"gpt_icon":0},{"id":"2588803114","title":"复星医药子公司肝素钠注射液注册申请获国家药监局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2588803114","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588803114?lang=zh_cn&edition=full","pubTime":"2025-12-02 18:06","pubTimestamp":1764669990,"startTime":"0","endTime":"0","summary":"12月2日，复星医药（600196/02196）发布公告，控股子公司药品注册申请获国家药品监督管理局受理。公告中提到，苏州二叶制药有限公司就肝素钠注射液的药品注册申请获得受理，该药品为公司自主研发的化学药品，主要用于防治静脉血栓和肺栓塞等多种医疗用途。截至2025年10月，苏州二叶在该药品上的累计研发投入约为861万元（未经审计）。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512023580474174.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1593","BK0028","BK0096","BK0196","600196","02196","BK0060","BK1515","BK0175","BK0187","BK0188","BK0183","BK1191","BK0239","BK0012"],"gpt_icon":0},{"id":"2588538083","title":"复星医药1类新药获批临床，太龙药业控制权生变，ST中珠子公司合同纠纷案获重审，福安药业头孢托仑匹酯颗粒过评","url":"https://stock-news.laohu8.com/highlight/detail?id=2588538083","media":"谈医说药","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588538083?lang=zh_cn&edition=full","pubTime":"2025-12-01 22:46","pubTimestamp":1764600404,"startTime":"0","endTime":"0","summary":"头孢托仑匹酯颗粒适用于敏感菌引起的浅表性皮肤感染、深部皮肤感染等疾病。复星医药：公司控股子公司上海复宏汉霖生物技术股份有限公司及其控股子公司收到国家药品监督管理局关于同意HLX37注射液开展临床试验的批准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251201233339a4c619a4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251201233339a4c619a4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","HK0000165453.HKD","02196","BK1593","BK1161","02696","BK1191"],"gpt_icon":0},{"id":"2588038540","title":"未履行报告程序擅自设立分支机构，“复星系”星恒保险代理一分公司被罚","url":"https://stock-news.laohu8.com/highlight/detail?id=2588038540","media":"北京商报","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588038540?lang=zh_cn&edition=full","pubTime":"2025-12-01 21:35","pubTimestamp":1764596110,"startTime":"0","endTime":"0","summary":"北京商报讯（记者李秀梅）12月1日，国家金融监督管理总局黑龙江监管局发布行政处罚信息显示，星恒保险代理有限责任公司黑龙江分公司，因未履行报告程序擅自设立分支机构，被警告并罚款3万元。时任星恒保险代理有限责任公司黑龙江分公司主要负责人尹文海，被警告并罚款1万元。官网信息介绍，星恒保险代理有限责任公司，为复星旗下具有网销资质的全国性保险专业代理机构，总部位于上海。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251201213802a4c5eacc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251201213802a4c5eacc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1593","02196","BK1191","BK1515"],"gpt_icon":0},{"id":"2588728927","title":"复星医药(600196.SH)控股子公司HLX37注射液获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2588728927","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588728927?lang=zh_cn&edition=full","pubTime":"2025-12-01 17:04","pubTimestamp":1764579890,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(600196.SH)发布公告，近日，公司控股子公司上海复宏汉霖生物技术股份有限公司及其控股子公司(合称“复宏汉霖”)收到国家药品监督管理局关于同意HLX37注射液(即重组人源化抗PD-L1与抗VEGF双特异性抗体注射液;简称“HLX37”)用于治疗晚期/转移性实体瘤患者开展临床试验的批准。复宏汉霖拟于条件具备后于中国境内开展HLX37的Ⅰ期临床试验。HLX37是集团自主研发的重组人源化抗PD-L1与抗VEGF双特异性抗体，拟用于治疗晚期/转移性实体瘤。截至目前的临床前研究表明，HLX37能够抑制肿瘤生长，且具有良好的安全性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1375989.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0183","BK0239","600196","BK1593","BK0012","BK0096","BK0175","BK0196","BK0028","BK0060","BK1515","BK0187","BK1191","02196","BK0188"],"gpt_icon":0},{"id":"2588385670","title":"每日卖空追踪 | 复星医药 12月01日卖空量成交4.2万股，卖空比例为1.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588385670","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588385670?lang=zh_cn&edition=full","pubTime":"2025-12-01 16:30","pubTimestamp":1764577828,"startTime":"0","endTime":"0","summary":"复星医药北京时间12月01日，涨1.91%，卖空量成交4.2万股，较上一交易日减少78.41%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251201163357a71c7193&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251201163357a71c7193&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1593","BK1191","BK1515","02196"],"gpt_icon":0},{"id":"2588038536","title":"复星医药12月01日获主力加仓443.0万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2588038536","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588038536?lang=zh_cn&edition=full","pubTime":"2025-12-01 16:16","pubTimestamp":1764576966,"startTime":"0","endTime":"0","summary":"12月01日, 复星医药股价涨1.91%，报收21.38元，成交金额5179.5万元，换手率0.45%，振幅2.29%，量比0.54。复星医药今日主力资金净流入443.0万元，连续6日净流入，上一交易日主力净流入91.2万元。该股近5个交易日上涨1.33%，主力资金累计净流入1217.2万元，其中3个交易日为股价下跌时净流入；近20日主力资金累计净流出312.9万元，其中净流出天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251201162258a71c6a34&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251201162258a71c6a34&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1593","BK1191","02196","BK1515"],"gpt_icon":0},{"id":"2588185747","title":"复星医药董事会通过多项关联交易续签及年度上限议案","url":"https://stock-news.laohu8.com/highlight/detail?id=2588185747","media":"中访网数据","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588185747?lang=zh_cn&edition=full","pubTime":"2025-11-30 08:49","pubTimestamp":1764463768,"startTime":"0","endTime":"0","summary":"中访网数据  上海复星医药(集团)股份有限公司于2025年11月28日召开第十届董事会第十五次会议，审议通过了多项关联交易续签及年度预计上限议案。此外，董事会还通过了2026年其他日常关联交易预计的议案。上述议案在表决时，相关关联董事均按规定回避表决，独立非执行董事已事前认可。这些决策旨在规范公司日常关联交易管理，确保业务运营的连续性和合规性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511300851569522102f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511300851569522102f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1593","02196","BK1191"],"gpt_icon":0},{"id":"2586738565","title":"复星医药（600196）披露关于召开2025年第二次临时股东会的提示性公告，11月28日股价下跌0.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586738565","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586738565?lang=zh_cn&edition=full","pubTime":"2025-11-28 22:13","pubTimestamp":1764339192,"startTime":"0","endTime":"0","summary":"截至2025年11月28日收盘，复星医药报收于27.13元，较前一交易日下跌0.29%，最新总市值为724.49亿元。公司近日发布公告称，上海复星医药（集团）股份有限公司将于2025年12月2日召开2025年第二次临时股东会，会议采用现场投票和网络投票相结合的方式，审议《关于选举执行董事的议案》。股权登记日为2025年11月26日，A股股东可于当日收市后在中国证券登记结算有限责任公司上海分公司登记在册参与投票。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112800039578.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0096","BK0028","BK0012","BK0196","BK1191","BK0060","BK1593","BK1515","BK0188","02196","BK0183","BK0187","600196","BK0239","BK0175"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.fosunpharma.com","stockEarnings":[{"period":"1week","weight":0.0238},{"period":"1month","weight":-0.0479},{"period":"3month","weight":-0.1109},{"period":"6month","weight":0.324},{"period":"1year","weight":0.551},{"period":"ytd","weight":0.551}],"compareEarnings":[{"period":"1week","weight":0.0087},{"period":"1month","weight":0.0058},{"period":"3month","weight":0.0262},{"period":"6month","weight":0.0964},{"period":"1year","weight":0.3336},{"period":"ytd","weight":0.3004}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海复星医药（集团）股份有限公司是一家主要从事医药产品研发、制造与销售的中国公司。该公司经营五个分部。制药分部主要从事创新药、成熟医药产品制造和疫苗业务。医疗器械与医学诊断分部主要从事分子诊断、免疫诊断、微生物诊断等医疗美容器械的制造和销售。医疗健康服务分部主要从事线上线下一体化医疗服务平台的经营。医药分销和零售分部主要从事医药产品的批发零售。其他分部从事其他医药相关业务。该公司的产品主要用于肿瘤、免疫、中枢神经等治疗领域。","yearOnYearQuotes":[{"month":1,"riseRate":0.384615,"avgChangeRate":-0.051338},{"month":2,"riseRate":0.769231,"avgChangeRate":0.040467},{"month":3,"riseRate":0.615385,"avgChangeRate":0.048431},{"month":4,"riseRate":0.384615,"avgChangeRate":0.03076},{"month":5,"riseRate":0.461538,"avgChangeRate":0.035265},{"month":6,"riseRate":0.461538,"avgChangeRate":-0.026545},{"month":7,"riseRate":0.615385,"avgChangeRate":0.027595},{"month":8,"riseRate":0.307692,"avgChangeRate":-0.041651},{"month":9,"riseRate":0.461538,"avgChangeRate":0.011609},{"month":10,"riseRate":0.461538,"avgChangeRate":0.020359},{"month":11,"riseRate":0.428571,"avgChangeRate":0.034495},{"month":12,"riseRate":0.5,"avgChangeRate":0.021694}],"exchange":"SEHK","name":"复星医药","nameEN":"FOSUN PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供复星医药(02196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"复星医药,02196,复星医药股票,复星医药股票老虎,复星医药股票老虎国际,复星医药行情,复星医药股票行情,复星医药股价,复星医药股市,复星医药股票价格,复星医药股票交易,复星医药股票购买,复星医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供复星医药(02196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}